Unity Biotechnology has yet to demonstrate that its drugs can treat diseases of aging in humans but it now has $85 million to start tests. The Brisbane, CA, drug developer priced its initial public offering of 5 million shares late Wednesday at $17 apiece. That price was the midpoint of the $16 to $18 range […]
Original Article: Unity Biotech IPO Raises $85M to Test Drugs for Diseases of Aging